IMODIUM MULTI-SYMPTOM RELIEF Drug Patent Profile
✉ Email this page to a colleague
When do Imodium Multi-symptom Relief patents expire, and when can generic versions of Imodium Multi-symptom Relief launch?
Imodium Multi-symptom Relief is a drug marketed by J And J Consumer Inc and is included in two NDAs.
The generic ingredient in IMODIUM MULTI-SYMPTOM RELIEF is loperamide hydrochloride; simethicone. There are eleven drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the loperamide hydrochloride; simethicone profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Imodium Multi-symptom Relief
A generic version of IMODIUM MULTI-SYMPTOM RELIEF was approved as loperamide hydrochloride; simethicone by PERRIGO R AND D on September 5th, 2018.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for IMODIUM MULTI-SYMPTOM RELIEF?
- What are the global sales for IMODIUM MULTI-SYMPTOM RELIEF?
- What is Average Wholesale Price for IMODIUM MULTI-SYMPTOM RELIEF?
Summary for IMODIUM MULTI-SYMPTOM RELIEF
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 25 |
| DailyMed Link: | IMODIUM MULTI-SYMPTOM RELIEF at DailyMed |
Recent Clinical Trials for IMODIUM MULTI-SYMPTOM RELIEF
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| MedSIR | Phase 2 |
| Gilead Sciences | Phase 2 |
| Naia Pharmaceuticals | Phase 1/Phase 2 |
Pharmacology for IMODIUM MULTI-SYMPTOM RELIEF
| Drug Class | Opioid Agonist |
| Mechanism of Action | Opioid Agonists |
| Physiological Effect | Skin Barrier Activity |
Paragraph IV (Patent) Challenges for IMODIUM MULTI-SYMPTOM RELIEF
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| IMODIUM MULTI-SYMPTOM RELIEF | Tablets | loperamide hydrochloride; simethicone | 2 mg/125 mg | 021140 | 2004-12-29 |
US Patents and Regulatory Information for IMODIUM MULTI-SYMPTOM RELIEF
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| J And J Consumer Inc | IMODIUM MULTI-SYMPTOM RELIEF | loperamide hydrochloride; simethicone | TABLET, CHEWABLE;ORAL | 020606-001 | Jun 26, 1996 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| J And J Consumer Inc | IMODIUM MULTI-SYMPTOM RELIEF | loperamide hydrochloride; simethicone | TABLET;ORAL | 021140-001 | Nov 30, 2000 | OTC | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for IMODIUM MULTI-SYMPTOM RELIEF
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| J And J Consumer Inc | IMODIUM MULTI-SYMPTOM RELIEF | loperamide hydrochloride; simethicone | TABLET, CHEWABLE;ORAL | 020606-001 | Jun 26, 1996 | ⤷ Sign Up | ⤷ Sign Up |
| J And J Consumer Inc | IMODIUM MULTI-SYMPTOM RELIEF | loperamide hydrochloride; simethicone | TABLET;ORAL | 021140-001 | Nov 30, 2000 | ⤷ Sign Up | ⤷ Sign Up |
| J And J Consumer Inc | IMODIUM MULTI-SYMPTOM RELIEF | loperamide hydrochloride; simethicone | TABLET, CHEWABLE;ORAL | 020606-001 | Jun 26, 1996 | ⤷ Sign Up | ⤷ Sign Up |
| J And J Consumer Inc | IMODIUM MULTI-SYMPTOM RELIEF | loperamide hydrochloride; simethicone | TABLET, CHEWABLE;ORAL | 020606-001 | Jun 26, 1996 | ⤷ Sign Up | ⤷ Sign Up |
| J And J Consumer Inc | IMODIUM MULTI-SYMPTOM RELIEF | loperamide hydrochloride; simethicone | TABLET;ORAL | 021140-001 | Nov 30, 2000 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for IMODIUM MULTI-SYMPTOM RELIEF
See the table below for patents covering IMODIUM MULTI-SYMPTOM RELIEF around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Germany | 69315257 | ⤷ Sign Up | |
| Australia | 7508898 | ⤷ Sign Up | |
| Canada | 2068402 | ENROBAGE POUR MASQUER LE GOUT POUVANT ETRE UTILISE DANS DES COMPRIMES PHARMACEUTIQUES CROQUABLES (TASTE MASK COATINGS FOR PREPARATION OF CHEWABLE PHARMACEUTICAL TABLETS) | ⤷ Sign Up |
| Spain | 2112387 | ⤷ Sign Up | |
| Czech Republic | 9802221 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for IMODIUM MULTI-SYMPTOM RELIEF
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0428296 | SPC/GB98/013 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE; REGISTERED: UK 00242/0314 19970923 |
| 0428296 | 99C0029 | Belgium | ⤷ Sign Up | PRODUCT NAME: LOPERAMIDUM HYDROCHOLORIDUM SEMITHICONUM; NATL. REGISTRATION NO/DATE: 2 IS 145 F3 19990201; FIRST REGISTRATION: GB PL 00242/0314 19970923 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
